



Appointment of new members to the Lumendo board of directors

Renens, February 16th, 2022. Welcome to our new board members! We are happy to announce that Simone Übele-Näscher and Andreas Meldau have joined Lumendo in the quest for revolutionary endodontic treatments. Andreas Meldau was elected by the Lumendo board of directors as President of the board.

As former President of the European Dental Group of Henry Schein, world's largest dental distributor, Mr. Meldau who has extensive experience in the dental industry, including one of the top IPOs in dentistry (Coltène Holding, CLTN) where he acted as CEO. Ms. Übele-Näscher brings extensive Finance and M&A experience to the Lumendo board of directors.

Together they will support Lumendo during its pre- and post-market-entry phases. With their long-standing expertise, they complement the Lumendo board perfectly.

About Andreas Meldau: Andreas holds a university degree in Law from the University of Zurich and a postgraduate diploma in Management from St. Gallen. 37 years of experience in the field of healthcare, including 10 years of IT, 7 years of medical technology, and 20 years of dental. International management responsibility in the development and expansion of companies and organizations, both in the manufacturing and in the retail environment. Andreas supports Lumendo with his knowledge in the areas of project management, market development, sales channels, and contracts.



About Simone Übele-Näscher: Simone is a Managing Partner of ValCap Services, a M&A boutique and investment/ start-up advisory. Prior to this, Mrs. Übele-Näscher worked at Acino International AG, a PE-backed international pharmaceutical company, in their Business Development and M&A department. Additional experiences she gained in PwC's M&A Advisory/ Transaction Services and Management Consulting department. She holds a university degree in Business and Automotive Engineering from University Stuttgart (Germany) and is a trained chartered accountant (ACCA). Simone Übele-Näscher supports Lumendo with her expertise in Business Development, M&A, Accounting, and Reporting.



About Lumendo: Incorporated in Switzerland in 2018 as Spin-off of the two Swiss Federal Institutes of Technology – École Polytechnique Fédéral de Lausanne (EPFL) and Eidgenössische Technische Hochschule Zürich (ETH) – Lumendo is a well-recognized upcoming disruptor in the field of endodontics. Focusing on



product excellence and a strong innovation stream, the goal of Lumendo is to develop easy-to-apply, reliable, and novel products to treat unsolved medical challenges.

About the technology: Root canal treatments are one of the most difficult treatments for dentists, traditionally with very low success rates between 46-91%¹. With more than 60 million annual treatments worldwide, these failures lead to a substantial increase in health care costs.

One major cause of the treatment failure can be traced back to the use of endodontic files that may result in root or instrument fractures. Another issue is the inefficient identification and disinfection of the often very complex root canal anatomy. Finally, a major problem is the obturation of these geometrically complex morphologies with viscous or rubber-like materials that are difficult to be distributed adequately in narrow canals, leading to voids that can be reinfected.

The goal of Lumendo's technology platform is to offer better treatment options to dentists and their patients. The company's first products are planned to be launched in 2024.

Disclaimer: Lumendo's devices are in development and not approved for clinical use under any jurisdiction.

For further information contact:

Lumendo AG

Chemin du Closel 5

CH-1020 Renens

Switzerland

info@lumendo.ch

www.lumendo.ch



¹ S. Friedman, "Prognosis of initial endodontic therapy," *Endod. Top.*, vol. 2, no. 1, pp. 59–88, Jul. 2002.